Health Note

From the Washington Post:

Food and Drug Administration advisers on Wednesday enthusiastically endorsed a first-of-its-kind cancer treatment that uses patients’ revved-up immune cells to fight the disease, concluding that the therapy’s benefits for desperately ill children far outweigh its potentially dangerous side effects….Novartis, the drugmaker behind the CAR T-cell therapy, is seeking approval to use it for children and young adults whose leukemia doesn’t respond to traditional treatments.

That’s great news for leukemia patients. But what about other blood cancers like—just picking one out of a hat here—multiple myeloma?

The approach also is being tested for a range of diseases from non-Hodgkin lymphoma and multiple myeloma to solid tumors. If cleared by the FDA, it would be the first gene therapy approved in the United States.

Great! In fact, the CAR T-cell treatment is already in clinical trials for multiple myeloma patients. In China:

Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small — 35 people — every patient responded and all but two were in some level of remission within two months.

….With cell therapy, “I can’t say we may get a cure but at least we bring hope of that possibility,” said Dr. Frank Fan. He is chief scientific officer of Nanjing Legend Biotech, a Chinese company that tested the treatment with doctors at Xi’an Jiaotong University….In the Chinese study, 19 of 35 patients are long enough past treatment to judge whether they are in complete remission, and 14 are. The other five had at least a partial remission, with their cancer greatly diminished. Some are more than a year past treatment with no sign of disease. 

After much serious thought, I would like to announce that I have changed my view about the disputed boundary lines in the South China Sea. China’s historical claim to the entire area is really beyond doubt, and only Western imperialist warmongery is keeping this “controversy” alive. China’s claims should be recognized by all nations forthwith.

BY THE WAY: In addition to my obviously personal interest here, this therapy is pretty interesting. Basically, they extract T cells from your body, freeze them, and then ship the bag of cells off to their lab. There, the ordinary T cells are genetically modified into super-vicious T cells and shipped back. The newly potent T cells are pumped back into your body, where they seek out cancerous cells and destroy them.

Will this therapy be ready by the time I need it? I hope so!

MORE HARD-HITTING JOURNALISM

In 2014, before Donald Trump announced his run for president, we knew we had to do something different to address the fundamental challenge facing journalism: how hard-hitting reporting that can hold the powerful accountable can survive as the bottom falls out of the news business.

Being a nonprofit, we started planning The Moment for Mother Jones, a special campaign to raise $25 million for key investments to make Mother Jones the strongest watchdog it can be. Five years later, readers have stepped up and contributed an astonishing $23 million in gifts and future pledges. This is an incredible statement from the Mother Jones community in the face of huge threats—both economic and political—against the free press.

Read more about The Moment and see what we've been able to accomplish thanks to readers' incredible generosity so far, and please join them today. Your gift will be matched dollar for dollar, up to $500,000 total, during this critical moment for journalism.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.